![Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525](https://oncodaily.com/pub/uploads/2024/06/Screenshot-460.png)
A collage of Michael Klichinsk and Carisma Therapeutics
Jun 27, 2024, 12:32
Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525
Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn:
“We are excited to share that Carisma Therapeutics received FDA Fast Track Designation for CT-0525 for the treatment of advanced HER2-overexpressing solid tumors.
More information here.”
Source: Michael Klichinsky/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023